Bionor files first clinical trial application for BIOSKILL

(Oslo, Norway, 17 November 2015) Bionor Pharma ASA (OSE:BIONOR) today announced the submission of a clinical trial application (CTA) to the Danish Medicines Agency requesting approval to initiate BIOSKILL in Denmark. BIOSKILL (BIOnor Shock and KILL) will enroll patients internationally and further CTAs will be submitted to national medicines agencies in the coming months.

Read more about Bionor files first clinical trial application for BIOSKILL

Financial Calendar 2016

(Oslo, Norway, 13 November 2015) Bionor Pharma ASA (OSE:BIONOR) has scheduled its financial calendar 2016 as follows:

Read more about Financial Calendar 2016

Q3 2015 Interim Financial Report

Bionor Pharma ASA
Interim Financial Report
1 January – 30 September 2015
Unaudited

Oslo, 3 November 2015

Read more about Q3 2015 Interim Financial Report

Strategic augmentation of Bionor’s Clinical Advisory Board emphasizes focus on functional HIV cure

(Oslo, Norway, 30 October 2015) Bionor Pharma ASA (OSE:BIONOR) has strengthened its Clinical Advisory Board with the appointment of Steven G. Deeks, Christine Katlama and Daniel Kuritzkes as part of the company’s revitalized strategic focus on Vacc-4x and functional HIV cure. The Clinical Advisory Board provides critical contributions to the development strategy and design of clinical trials, including BIOSKILL.

Read more about Strategic augmentation of Bionor’s Clinical Advisory Board emphasizes focus on functional HIV cure

Notice of results for the nine months ended 30 September 2015

(Oslo, Norway, 27 October 2015) Bionor Pharma ASA (OSE:BIONOR) will report its financial results for the nine months ended 30 September 2015 on 3 November 2015 at 08:00am CET.

Read more about Notice of results for the nine months ended 30 September 2015

Bionor to present anticipated next steps to value creation at its Capital Markets Day in Oslo today

(Oslo, Norway, 7 October 2015) Bionor Pharma ASA (Bionor) (OSE:BIONOR), a Norwegian biopharmaceutical company focused on developing its proprietary therapeutic vaccine Vacc-4x for HIV, will today host a Capital Markets Day for institutional and private investors and financial analysts from 12:00-15:30 CEST at the Hotel Continental, Stortingsgata 24-26, 0117 Oslo, Norway.

Read more about Bionor to present anticipated next steps to value creation at its Capital Markets Day in Oslo today

Capital Markets Day 2015

(Oslo, Norway, 23 September 2015) Bionor Pharma ASA (Bionor) (OSE:BIONOR), a Norwegian biopharmaceutical company focused on developing its proprietary therapeutic vaccine Vacc-4x for HIV, will host a Capital Markets Day for institutional and private investors and financial analysts in Oslo on 7 October 2015 at 12:00-15:30 CEST.

Read more about Capital Markets Day 2015

Results of the REDUC study Part A published in the journal PLoS Pathogens

(Oslo, Norway, 18 September 2015) Bionor Pharma ASA (Bionor) (OSE:BIONOR), a peptide vaccine company advancing a potential first therapeutic vaccine towards a functional cure for HIV, today announces the publication of the manuscript “The Depsipeptide Romidepsin Reverses HIV-1 Latency in vivo” in the peer-reviewed journal PLoS Pathogens. Ole Schmeltz Søgaard from Aarhus University Hospital in Denmark is corresponding author of the manuscript, which describes the results from Part A of the Bionor sponsored REDUC study presented at the IAS 2014 conference in Melbourne.

Read more about Results of the REDUC study Part A published in the journal PLoS Pathogens

Share capital increase registered

(Oslo, 17 August 2015) With reference to the announcement made on 23 June 2015 regarding issuance of shares to members of the Board of Directors of Bionor as resolved by the Annual General Meeting on 13 May 2015, the share capital increase has now been registered in the Companies Register.

Read more about Share capital increase registered

Bionor announces option issue to key employees

(Oslo, Norway, 12 August 2015) The Board of Directors of Bionor Pharma ASA (Bionor) (OSE:BIONOR), a peptide vaccine company advancing a potential first therapeutic vaccine towards a functional cure for HIV, has approved an updated option program for the next four year period, pending the continuing support of the shareholders through yearly grants of authorizations for share issues under the company’s incentive program.

Read more about Bionor announces option issue to key employees

H1 2015 Interim Financial Report

Bionor Pharma ASA
Interim Financial Report
1 January – 30 June 2015
Unaudited

Oslo, 12 August 2015

Read more about H1 2015 Interim Financial Report

Bionor notice of results for the six months ended 30 June 2015

(Oslo, Norway, 5 August 2015) Bionor Pharma ASA (OSE:BIONOR), a peptide vaccine company advancing the potential first therapeutic vaccine towards a functional cure for HIV, will report its half year financial results for the six months ended 30 June 2015 on 12 August 2015 at 07:30am CEST.

Read more about Bionor notice of results for the six months ended 30 June 2015

Bionor enters into romidepsin supply agreement enabling advancement of its HIV therapeutic vaccine with Vacc-4x into full scale clinical Phase II

(Oslo, Norway, 16 July 2015) Bionor Pharma ASA (Bionor) (OSE:BIONOR), a peptide vaccine company advancing a potential first therapeutic vaccine towards a functional cure for HIV, has signed an agreement with Celgene Corporation (Celgene) securing a continued supply of romidepsin (Istodax®) for use in a planned multicenter clinical Phase II study of Bionor’s most advanced and proprietary vaccine, Vacc-4x, with romidepsin.

The planned study will continue to explore the “Kick and Kill” strategy of Bionor’s ongoing REDUC study, for which Celgene also supplies romidepsin. In Part A of the REDUC study, completed in 2014, it was demonstrated that romidepsin was safe, well tolerated and able to release HIV viral DNA from latent reservoirs into the blood stream in HIV infected patients on anti-retroviral treatment. An interim analysis of Part B of the REDUC study announced on 4 May 2015 indicated killing of reactivated HIV and reduction in latent viral reservoir when patients received Vacc-4x prior to romidepsin.

David H. Solomon, President and CEO comments:
This agreement with Celgene is very important for us. In our view, it’s a recognition of Bionor’s therapeutic vaccine approach to a functional cure for HIV and consistent with our reinvigorated strategic intent to focus on further advancement of Vacc-4x in combination with a latency reversing agent. Bionor is the only company which has an HIV vaccine together with a latency reversing agent in humans in clinical trials, and we have intriguing and promising results from the REDUC study showing that romidepsin worked to kick the latent virus out of the reservoirs, and that the addition of Vacc-4x indicated killing of reactivated HIV. With the new supply agreement we have taken a great step forward in our preparation of the next full scale Phase II study with the aim to obtain significant proof, that a Kick and Kill strategy combining Vacc-4x with an HDAC inhibitor is the likely path to a functional cure for HIV.

As announced on 5 May 2015, Bionor is currently preparing a proof of concept clinical Phase II study of 
Vacc-4x together with romidepsin with the aim of investigating the contribution of Vacc-4x as a component in a functional cure for HIV. Planning of the contemplated clinical trial is ongoing, but no final decisions have yet been taken with respect to design, timing or size of the clinical trial.
    
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Further information
David H. Solomon, President and CEO
M: +45 22 20 63 00
E: dhs@bionorpharma.com


Jørgen F. Ravn, VP Investor Relations & Communications
M: +45 20 30 39 03
E: jfr@bionorpharma.com

About Bionor

Bionor Pharma ASA is a leading biotechnology company advancing a potential first therapeutic vaccine towards a functional cure for HIV. The company's focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor’s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Bionor’s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study.

Bionor is headquartered in Oslo, Norway, with offices in Copenhagen and New York, and is listed on the Oslo stock exchange, under the ticker BIONOR. More information about Bionor is available at www.bionorpharma.com.

Share capital increase registered

(Oslo, Norway, 23 June 2015) With reference to the announcement made on 18 June 2015 regarding issuance of shares to former employee Birger Sørensen under a share option agreement, the share capital increase has now been registered in the Companies Register.

Read more about Share capital increase registered

Bionor Pharma ASA issues shares to board members

(Oslo, Norway, 23 June 2015) In accordance with the resolution by the Annual General Meeting of Bionor Pharma ASA (OSE: BIONOR) on 13 May 2015, all board members have been offered to subscribe shares in the Company valued at NOK 100,000 and the Chairman of the Board has been offered to subscribe shares valued at NOK 200,000.

Read more about Bionor Pharma ASA issues shares to board members

Exercise of share options

(Oslo, Norway, 18 June 2015) The Board of Directors of Bionor Pharma ASA (OSE:BIONOR) has resolved to issue 666,667 new shares in the Company based on options exercised by former employee Birger Sørensen.

Read more about Exercise of share options

Bionor appoints new Chairman and three Non-Executive Directors

(Oslo, Norway, 13 May 2015) Bionor Pharma ASA (OSE:BIONOR), a peptide vaccine company advancing the potential first therapeutic vaccine towards a functional cure for HIV announces, following today’s Annual General Meeting, the appointment of a new Chairman and three Non-Executive Directors.

Read more about Bionor appoints new Chairman and three Non-Executive Directors

Bionor Pharma: Annual General Meeting Approves All Items

(Oslo, 13 May 2015) The Annual General Meeting of Bionor Pharma ASA today adopted all the items as proposed on the agenda.

Read more about Bionor Pharma: Annual General Meeting Approves All Items

Bionor Pharma - First Quarter 2015 results

(Oslo, 13.05.2015) Bionor Pharma ASA (OSE: BIONOR) announced today its financial results for the first quarter 2015 and update on its clinical development program.

Read more about Bionor Pharma - First Quarter 2015 results

Bionor appoints Vice President for Investor Relations and Communications

(Oslo, Norway, 12 May 2015) Bionor Pharma ASA (OSE:BIONOR), a peptide vaccine company advancing the potential first therapeutic vaccine towards a functional cure for HIV, today announces the appointment of Jørgen Fischer Ravn as Vice President for Investor Relations and Communications. Jørgen will join the company 1 June 2015.

Read more about Bionor appoints Vice President for Investor Relations and Communications

Bionor appoints new Chief Financial Officer

(Oslo, Norway, 6 May 2015) Bionor Pharma ASA (OSE:BIONOR), a peptide vaccine company advancing the potential first therapeutic vaccine towards a functional cure for HIV, today announces the appointment of Jens Krøis as its Chief Financial Officer.

Read more about Bionor appoints new Chief Financial Officer

Invitation to Annual General Meeting 13 May 2015 Updated

Oslo, 21 April 2015 - The Annual General Meeting of Bionor Pharma ASA will be held on Wednesday 13 May 2014, 11:00 a.m. at Hotel Continental, Stortingsgaten 24/26, Oslo

Read more about Invitation to Annual General Meeting 13 May 2015 Updated

Change of Date for Q1 2015 Report and Annual General Meeting

(Oslo 13 April 2015) Bionor Pharma ASA has changed the date for announcement for its first quarter 2015 results and Annual General Meeting to 13 May 2015.

Read more about Change of Date for Q1 2015 Report and Annual General Meeting

Invitation to Annual General Meeting 13 May 2015

Oslo, 13 April 2015 - The Annual General Meeting of Bionor Pharma ASA will be held on Wednesday 13 May 2014, 11:00 a.m. at Hotel Continental, Stortingsgaten 24/26, Oslo

Read more about Invitation to Annual General Meeting 13 May 2015

Bionor announces additions to the executive management team and interim CFO

(Oslo, 27.03.2015) Bionor Pharma ASA (OSE:BIONOR) announces new members of the executive management team joining CEO, Dr. David Horn Solomon.

Read more about Bionor announces additions to the executive management team and interim CFO

Bionor Pharma - Fourth Quarter 2014 results

(Oslo, 25.02.2015) Bionor Pharma ASA (OSE: BIONOR) announced today its financial results for the fourth quarter and preliminary full year 2014 and update on its clinical development program.

Read more about Bionor Pharma - Fourth Quarter 2014 results

Invitation to Webcast of Bionor Pharma Q4 2014 Results 25 February

Bionor Pharma ASA (OSE:BIONOR) will announce its fourth quarter 2014 results Wednesday 25 February 2015 at 7.00 CET.

Read more about Invitation to Webcast of Bionor Pharma Q4 2014 Results 25 February

Mandatory Notification of Trade

(Oslo, Norway, 13 February 2015) Bionor Pharma ASA Director Marianne Kock purchased 7,469 shares in Bionor Pharma ASA the 20.01.2015 at an average price of NOK 2.34.

Read more about Mandatory Notification of Trade

Administration Update

(Oslo, 03.02.2015) Bionor Pharma ASA announces that the Company has received a waiver under the Public Limited Liability Companies Act section 6-11 for the appointment of David Solomon as CEO.

Read more about Administration Update

Change of Date for Q4 2014 Report

(Oslo 26 January 2015) Bionor Pharma ASA has changed the date for announcement for its fourth quarter 2014 results to 25 February 2015.

Bionor Pharma Announces Interim Administration

(Oslo, 25 January 2015). Reference is made to the announcement on 9 January regarding the employment of Dr. David H. Solomon as new CEO of Bionor Pharma ASA.

Read more about Bionor Pharma Announces Interim Administration

Bionor Pharma ASA – Issue of Share Options

(Oslo, 12 January 2015) Reference is made to the announcement of the appointment of David Horn Solomon as the new CEO of Bionor Pharma ASA 9 January 2015.

Read more about Bionor Pharma ASA – Issue of Share Options

David Horn Solomon assumes the role as President and Chief Executive Officer of Bionor Pharma ASA

(Oslo, 9 January, 2015) Bionor Pharma ASA announces the appointment of Dr David Horn Solomon as new President and Chief Executive Officer.

Read more about David Horn Solomon assumes the role as President and Chief Executive Officer of Bionor Pharma ASA

Bionor Pharma ASA: Synne H. Røine resigns as CFO

(Oslo, Norway, 2 January 2015) Ms. Synne H. Røine resigns as CFO in Bionor Pharma ASA to accept an executive position in a private equity held Norwegian based company from 1. April 2015.

Read more about Bionor Pharma ASA: Synne H. Røine resigns as CFO